# Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)

> **NCT01381536** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** GSK1550188 1mg/kg or 10mg/kg

## Key facts

- **NCT ID:** NCT01381536
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-20
- **Primary completion:** 2010-11-27
- **Final completion:** 2010-11-27
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381536, "Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01381536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*